Login to Your Account



Pharma: Other News To Note


Wednesday, November 27, 2013
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said its marketing authorization application for faldaprevir, a second-generation oral protease inhibitor, was fully validated and granted accelerated assessment by the European Medicines Agency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription